Boston Scientific Corp (BSX)vsPerspective Therapeutics Inc. (CATX)
BSX
Boston Scientific Corp
$48.55
+0.76%
HEALTHCARE · Cap: $69.50B
CATX
Perspective Therapeutics Inc.
$3.03
-6.77%
HEALTHCARE · Cap: $335.30M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 3335499% more annual revenue ($20.61B vs $618,000). BSX leads profitability with a 17.3% profit margin vs 0.0%. BSX earns a higher WallStSmart Score of 76/100 (B+).
BSX
Strong Buy76
out of 100
Grade: B+
CATX
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-25.6%
Fair Value
$37.35
Current Price
$48.55
$11.20 premium
Intrinsic value data unavailable for CATX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
No major concerns identified
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : CATX
The strongest argument for CATX centers on Price/Book, Debt/Equity.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Bear Case : CATX
The primary concerns for CATX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
BSX profiles as a mature stock while CATX is a value play — different risk/reward profiles.
CATX carries more volatility with a beta of 1.73 — expect wider price swings.
BSX is growing revenue faster at 11.6% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (76/100 vs 30/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Perspective Therapeutics Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Perspective Therapeutics Inc. (CATX) is a pioneering biotechnology firm focused on revolutionizing cancer care through the development of innovative radiopharmaceuticals. Leveraging state-of-the-art radioisotope technologies, CATX seeks to enhance the precision and effectiveness of cancer therapies, aiming to significantly improve patient survival rates across various malignancies. Backed by a seasoned leadership team and strong strategic alliances, the company is strategically positioned to drive advancements in targeted cancer treatments, addressing significant healthcare challenges in a competitive landscape.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?